ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TGTX / forecast
PTGX (65) MDGL (38) CORT (63) CYTK (28) ⌘ Pro Terminal →

TG Therapeutics Inc. (TGTX) 12-Month Stock Forecast & Price Target Cone

$59.95 -2.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.62

TG Therapeutics Inc. (TGTX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $9.36B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TGTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, TG Therapeutics Inc. (NASDAQ: TGTX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $59.95 (-2.01% 1D, market cap $9.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TGTX ranks #135 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TGTX compare to PTGX and MDGL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TGTX carries a Roarable C (63/100 RQD), trailing P/E of 19.9x, gross margin of 83.7%, and ROIC of 12.0%. By comparison, PTGX (Protagonist Therapeutics Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TGTX?
▼

Per TGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001001316), TG Therapeutics Inc. generated $616.3M in revenue (+87.3% YoY), $447.2M in net income, and -$25.0M in free cash flow against $1.06B in total assets and $245.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $59.62 (-0.55%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510063
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C- · Rk C+
Cash (9)Whales (18)SEC (16)Macro (11)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
$72 Bull$61 Base$48 Bear
📬 FREE TGTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TGTX)Realized 20D OHLCV Swing Band: ±8.4%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY TGTX SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (29% of score)

20D Institutional Volume Accumulation (±8.4% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 12.92 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$54.37-2.2% Next Q
Q2 (-2Q)
58
Grade C$53.20+7.9% Next Q
Q3 (-1Q)
60
Grade C$57.40+4.4% Next Q
Current
63
Grade C$59.95+0.9% Hist 90D α
Trajectory: C (55) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TGTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, TGTX faces multiple-compression risk if 19.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.80% YoY Shares) — any gross margin slip below 81.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($55.56) or 200D SMA ($44.23) invalidates the momentum regime and cuts Target Base ($61.30) toward Bear Floor ($47.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TGTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TGTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 63%NO 37%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your TGTX Position Size: $10,000

Shares at $59.95: 166.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $47.81
$7,975
$-2,025 (-20.3%)
12M Consensus BaseTarget $61.30
$10,225
+$225 (+2.3%)
12M Bull Case BreakoutTarget $72.33
$12,065
+$2,065 (+20.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$6474%A
Goldman SachsSector Coverage LeadBUY$6869%B
JP MorganUS Large-Cap ResearchHOLD$5558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (TGTX Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TGTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +67.88%⚡ TESTING RESISTANCE
2026-11-03O $58.08H $61.18L $58.08C $59.95VOL 2.86M
RES: $62.01SUP: $52.74SMA50: $55.56SMA200: $44.23
$63.85$55.18$46.50$37.82$29.15RES $62.01SUP $52.74$59.952026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TGTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TGTX Butterfly Map → + Track TGTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.4%/yr Implied 5Y Growth

vs. +87.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TGTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TGTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TGTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TGTX)

Health Care Rank #135 of 1015 ⚔️ PTGX vs TGTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TGTX vs. PTGX, MDGL, CORT, CYTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, TG Therapeutics Inc. (TGTX) ranks #135 by composite RQD confidence (63/100, grade C) and #118 by equity capitalization ($9.36B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TGTX at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TGTX ACTIVE
TG Therapeutics Inc.
C 63/100 19.9x 83.7% 12.0% -2.01% $9.36B Benchmark Subject
PTGX
Protagonist Therapeutics Inc.
C 65/100 — — -16.7% -3.78% $9.37B /ptgx-vs-tgtx →
MDGL
Madrigal Pharmaceuticals Inc.
D- 38/100 — — -29.7% +0.19% $9.94B /mdgl-vs-tgtx →
CORT
Corcept Therapeutics Incorporated
C 63/100 93.2x 96.0% 4.8% -0.81% $8.77B /cort-vs-tgtx →
CYTK
Cytokinetics Incorporated
E 28/100 — — -35.0% -1.52% $8.76B /cytk-vs-tgtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001001316 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TG Therapeutics Inc. (TGTX) reported GAAP revenue of $616.3M (+87.3% vs. FY2024 revenue of $329.0M , and +163.8% cumulative change since FY2023) , GAAP net income of $447.2M, operating cash flow of -$24.8M, and free cash flow of -$25.0M (+38.4% YoY). On the balance sheet, TGTX closed FY2025 with $1.06B in total assets against $245.6M in total debt (Altman Z-Score: 12.92, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $616.3M $447.2M -$24.8M -$25.0M $1.06B $245.6M
FY2024 (FY) 2024-12-31 $329.0M $23.4M -$40.5M -$40.6M $577.7M $244.4M
FY2023 (FY) 2023-12-31 $233.7M $12.7M -$31.4M -$41.9M $4.89B $1.14B

3. TGTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TGTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, TG Therapeutics Inc. (NASDAQ: TGTX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $59.95 (-2.01% 1D, market cap $9.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TGTX ranks #135 in composite RQD confidence.

How does TGTX compare to PTGX and MDGL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TGTX carries a Roarable C (63/100 RQD), trailing P/E of 19.9x, gross margin of 83.7%, and ROIC of 12.0%. By comparison, PTGX (Protagonist Therapeutics Inc.) holds a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TGTX?

Per TGTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001001316), TG Therapeutics Inc. generated $616.3M in revenue (+87.3% YoY), $447.2M in net income, and -$25.0M in free cash flow against $1.06B in total assets and $245.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TGTX trading relative to its 50-day, 200-day, and 52-week technical levels?

TGTX last traded at $59.95 (-2.01% on volume of 2,576,446 shares), positioning the stock +7.90% above its 50-day simple moving average ($55.56) and +35.54% above its 200-day simple moving average ($44.23). Across its 52-week range of $26.76 to $61.76, TGTX sits at the 94.8% percentile with a 14-day RSI of 64.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.4% ($54.91 to $64.99).

Direct Sub-Reports: TGTX RQD Cockpit TGTX 12M Forecast TGTX Earnings & Move TGTX Dividends & DRIP TGTX Insiders & 13F TGTX Whale Options TGTX Profit Sankey TGTX News & Why
ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

TGTX — TG Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

TG Therapeutics Inc. (TGTX) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $59.95 (-2.01% 1D, market capitalization $9.36B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 12.0%, gross margin of 83.7%, operating margin of 20.0%, and free cash flow yield of -0.28%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 0.87x equity beta, Altman Z-Score of 12.92, Piotroski F-Score of 6/9, and Debt/Equity of 0.38x.

2. Business Model, Unit Margins & SEC Financial Trajectory

TG Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile identifies a market capitalization of $8.9B. Recent news items reference multiple sclerosis clinical data presented at MSToronto2026, per the Recent Catalysts section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TG Therapeutics Inc. (TGTX) reported $616.3M in annual revenue (up from $329.0M in FY2024, +87.3% YoY) and $447.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($233.7M revenue, $12.7M net income) through FY2025, TGTX scaled operating cash flow to -$24.8M and free cash flow to -$25.0M, backed by $1.06B in total assets against $245.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 63/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $26.76 – $61.76 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 19.9x trailing P/E and 73.3x EV/EBITDA against 20.0% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TGTX carries a macro regime beta of 0.87 and gross margin of 83.7%.

  • Key Question #1: Can TGTX sustain or expand its 20.0% operating margin and 12.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $616.3M and free cash flow of -$25.0M, how will capital allocation balance growth reinvestment against $245.6M in total debt?
  • Key Question #3: How sensitive is TGTX's 16.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

TGTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TG Therapeutics Inc. (TGTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TGTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TGTX Bull vs. Bear Conversation Board — What's Your Call at $59.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TGTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TGTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $76.47 (+25.0%)
📌 Pinned Debate

Institutional accumulation scores 17 of 20 in the RQD rating, and the Altman Z-Score of 12.92 signals strong balance sheet forensics.

Don't sleep on TGTX's setup in Health Care. Institutional accumulation scores 17 of 20 in the RQD rating, and the Altman Z-Score of 12.92 signals strong balance sheet forensics.. Beta of 0.87 means it moves fast when momentum turns, and the 5-pillar RQD gauge (63/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RedlineAuditor Fair point on 19.9x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (83.7%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $49.56 (-19.0%)
Spot @ $61.18

Free cash flow was negative in all three reported periods and the FCF yield is -0.28%, while EV/EBITDA sits at 73.3.

Here is the bear case nobody on the bull side wants to address on TGTX: Free cash flow was negative in all three reported periods and the FCF yield is -0.28%, while EV/EBITDA sits at 73.3.. At 19.9x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE